Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 pivotal trial of ADX-2191

Next Previous
Trial Profile

Phase 2/3 pivotal trial of ADX-2191

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methotrexate (Primary)
  • Indications Retinitis pigmentosa
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 31 Oct 2024 According to an Aldeyra Therapeutics media release, company announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024.
  • 25 Apr 2024 According to Aldeyra Therapeutics, Inc. media release, the Company will announce a planned pivotal clinical trial in retinitis pigmentosa, at 2024 Research & Development Day and financial analysts in New York City.
  • 25 Apr 2024 According to Aldeyra Therapeutics, Inc. media release, based on recent discussions with the U.S. Food and Drug Administration (the FDA), Aldeyra intends to initiate a potentially pivotal Phase 2/3 clinical trial of investigational product candidate ADX-2191 (methotrexate injection, USP) in patients with retinitis pigmentosa due to rhodopsin misfolding mutations.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top